Visual Abstract

Background: A significant number of heart failure (HF) patients with reduced left ventricular ejection fraction (LVEF) experience ventricular function recovery during follow-up. We studied the variables associated with LVEF recovery in patients treated with sacubitril/valsartan (SV) in clinical practice. Methods: We analyzed data from a prospective and multicenter registry including 249 HF outpatients with reduced LVEF who started SV between October 2016 and March 2017. The patients were classified into 2 groups according to LVEF at the end of follow-up (>35%: group R, or ≤35%: group NR). Results: After a mean follow-up of 7 ± 0.1 months, 62 patients (24.8%) had LVEF >35%. They were older (71.3 ± 10.8 vs. 67.5 ± 12.1 years, p = 0.025), and suffered more often from hypertension (83.9 vs. 73.8%, p = 0.096) and higher blood pressure before and after SV (both, p < 0.01). They took more often high doses of beta-blockers (30.6 vs. 27.8%, p = 0.002), with a smaller proportion undergoing cardiac resynchronization therapy (14.8 vs. 29.0%, p = 0.028) and fewer implanted cardioverter defibrillators (ICD; 32.8 vs. 67.9%, p < 0.001), this being the only predictive variable of NR in the multivariate analysis (OR 0.26, 95% CI 0.13–0.47, p < 0.0001). At the end of follow-up, the mean LVEF in group R was 41.9 ± 8.1% (vs. 26.3 ± 4.7% in group NR, p < 0.001), with an improvement compared with the initial LVEF of 14.6 ± 10.8% (vs. 0.8 ± 4.5% in group NR, p < 0.0001). Functional class improved in both groups, mainly in group R (p = 0.035), with fewer visits to the emergency department (11.5 vs. 21.6%, p = 0.07). Conclusions: In patients with LVEF ≤35% treated with SV, not carrying an ICD was independently associated with LVEF recovery, which was related to greater improvement in functional class.

1.
Roger
VL
,
Go
AS
,
Lloyd-Jones
DM
,
Benjamin
EJ
,
Berry
JD
,
Borden
WB
, et al;
American Heart Association Statistics Committee and Stroke Statistics Subcommittee
.
Heart disease and stroke statistics—2012 update: a report from the American Heart Association
.
Circulation
.
2012
Jan
;
125
(
1
):
e2
220
.
[PubMed]
1524-4539
2.
Díez-Villanueva
P
,
Alfonso
F
.
Heart failure in the elderly
.
J Geriatr Cardiol
.
2016
Feb
;
13
(
2
):
115
7
.
[PubMed]
1671-5411
3.
Sayago-Silva
I
,
García-López
F
,
Segovia-Cubero
J
.
Epidemiology of heart failure in Spain over the last 20 years
.
Rev Esp Cardiol (Engl Ed)
.
2013
Aug
;
66
(
8
):
649
56
.
[PubMed]
1885-5857
4.
Llorens
P
,
Javaloyes
P
,
Martín-Sánchez
FJ
,
Jacob
J
,
Herrero-Puente
P
,
Gil
V
, et al;
ICA-SEMES Research Group
.
Time trends in characteristics, clinical course, and outcomes of 13,791 patients with acute heart failure
.
Clin Res Cardiol
.
2018
Oct
;
107
(
10
):
897
913
.
[PubMed]
1861-0684
5.
Ponikowski
P
,
Voors
AA
,
Anker
SD
,
Bueno
H
,
Cleland
JG
,
Coats
AJ
, et al;
Authors/Task Force Members
;
Document Reviewers
.
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC
.
Eur J Heart Fail
.
2016
Aug
;
18
(
8
):
891
975
.
[PubMed]
1388-9842
6.
McMurray
JJ
,
Packer
M
,
Desai
AS
,
Gong
J
,
Lefkowitz
MP
,
Rizkala
AR
, et al;
PARADIGM-HF Investigators and Committees
.
Angiotensin-neprilysin inhibition versus enalapril in heart failure
.
N Engl J Med
.
2014
Sep
;
371
(
11
):
993
1004
.
[PubMed]
0028-4793
7.
Binkley
PF
,
Lesinski
A
,
Ferguson
JP
,
Hatton
PS
,
Yamokoski
L
,
Hardikar
S
, et al
Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event
.
Am Heart J
.
2008
Jan
;
155
(
1
):
69
74
.
[PubMed]
0002-8703
8.
Merlo
M
,
Pyxaras
SA
,
Pinamonti
B
,
Barbati
G
,
Di Lenarda
A
,
Sinagra
G
.
Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment
.
J Am Coll Cardiol
.
2011
Mar
;
57
(
13
):
1468
76
.
[PubMed]
0735-1097
9.
Wilcox
JE
,
Fonarow
GC
,
Yancy
CW
,
Albert
NM
,
Curtis
AB
,
Heywood
JT
, et al
Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF
.
Am Heart J
.
2012
Jan
;
163
(
1
):
49
56.e2
.
[PubMed]
0002-8703
10.
Lupón
J
,
Díez-López
C
,
de Antonio
M
,
Domingo
M
,
Zamora
E
,
Moliner
P
, et al
Recovered heart failure with reduced ejection fraction and outcomes: a prospective study
.
Eur J Heart Fail
.
2017
Dec
;
19
(
12
):
1615
23
.
[PubMed]
1388-9842
11.
Valika
A
,
Paprockas
K
,
Villines
D
,
Costanzo
MR
.
Importance of baseline heart rate as a predictor of cardiac functional recovery in newly diagnosed heart failure with reduced ejection fraction
.
Clin Cardiol
.
2018
Jun
;
41
(
6
):
752
7
.
[PubMed]
0160-9289
12.
Amor-Salamanca
A
,
Guzzo-Merello
G
,
González-López
E
,
Domínguez
F
,
Restrepo-Córdoba
A
,
Cobo-Marcos
M
, et al
Prognostic Impact and Predictors of Ejection Fraction Recovery in Patients With Alcoholic Cardiomyopathy
.
Rev Esp Cardiol (Engl Ed)
.
2018
Aug
;
71
(
8
):
612
9
.
[PubMed]
1885-5857
13.
Lang
RM
,
Badano
LP
,
Mor-Avi
V
,
Afilalo
J
,
Armstrong
A
,
Ernande
L
, et al
Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
.
Eur Heart J Cardiovasc Imaging
.
2015
Mar
;
16
(
3
):
233
70
.
[PubMed]
2047-2404
14.
Senni
M
,
McMurray
JJ
,
Wachter
R
,
McIntyre
HF
,
Reyes
A
,
Majercak
I
, et al
Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens
.
Eur J Heart Fail
.
2016
Sep
;
18
(
9
):
1193
202
.
[PubMed]
1388-9842
15.
Solomon
SD
,
Anavekar
N
,
Skali
H
,
McMurray
JJ
,
Swedberg
K
,
Yusuf
S
, et al;
Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators
.
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients
.
Circulation
.
2005
Dec
;
112
(
24
):
3738
44
.
[PubMed]
0009-7322
16.
Komajda
M
,
Böhm
M
,
Borer
JS
,
Ford
I
,
Tavazzi
L
,
Pannaux
M
, et al
Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis
.
Eur J Heart Fail
.
2018
Sep
;
20
(
9
):
1315
22
.
[PubMed]
1388-9842
17.
Garg
R
,
Yusuf
S
;
Collaborative Group on ACE Inhibitor Trials
.
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
.
JAMA
.
1995
May
;
273
(
18
):
1450
6
.
[PubMed]
0098-7484
18.
Yusuf
S
,
Pitt
B
,
Davis
CE
,
Hood
WB
,
Cohn
JN
;
SOLVD Investigators
.
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
.
N Engl J Med
.
1991
Aug
;
325
(
5
):
293
302
.
[PubMed]
0028-4793
19.
CONSENSUS Trial Study Group
.
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
.
N Engl J Med
.
1987
Jun
;
316
(
23
):
1429
35
.
[PubMed]
0028-4793
20.
Agra Bermejo
R
,
Gonzalez Babarro
E
,
López Canoa
JN
,
Varela Román
A
,
Gómez Otero
I
,
Oro Ayude
M
, et al
Heart failure with recovered ejection fraction: clinical characteristics, determinants and prognosis. CARDIOCHUS-CHOP registry
.
Cardiol J
.
2018
;
25
(
3
):
353
62
.
[PubMed]
1897-5593
21.
Martínez-Sellés
M
,
Díez-Villanueva
P
,
Álvarez Garcia
J
,
Ferrero-Gregori
A
,
Vives-Borrás
M
,
Worner
F
, et al
Influence of sex and pregnancy on survival in patients admitted with heart failure: data from a prospective multicenter registry
.
Clin Cardiol
.
2018
Jul
;
41
(
7
):
924
30
.
[PubMed]
0160-9289
22.
Ferreira
JP
,
Metra
M
,
Mordi
I
,
Gregson
J
,
Ter Maaten
JM
,
Tromp
J
, et al
Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study
.
Eur J Heart Fail
.
2018
Oct
;
•••
: ; [
Epub ahead of print
].
[PubMed]
1388-9842
23.
Chandra
A
,
Lewis
EF
,
Claggett
BL
,
Desai
AS
,
Packer
M
,
Zile
MR
, et al
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial
.
JAMA Cardiol
.
2018
Jun
;
3
(
6
):
498
505
.
[PubMed]
2380-6583
24.
Packer
M
,
McMurray
JJ
,
Desai
AS
,
Gong
J
,
Lefkowitz
MP
,
Rizkala
AR
, et al;
PARADIGM-HF Investigators and Coordinators
.
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure
.
Circulation
.
2015
Jan
;
131
(
1
):
54
61
.
[PubMed]
0009-7322
25.
Desai
AS
,
Claggett
BL
,
Packer
M
,
Zile
MR
,
Rouleau
JL
,
Swedberg
K
, et al;
PARADIGM-HF Investigators
.
Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization
.
J Am Coll Cardiol
.
2016
Jul
;
68
(
3
):
241
8
.
[PubMed]
0735-1097
26.
Vicent
L
,
Esteban-Fernández
A
,
Gómez-Bueno
M
,
De-Juan
J
,
Díez-Villanueva
P
,
Iniesta
ÁM
, et al
Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial
.
J Cardiovasc Pharmacol
.
2018
Aug
;
72
(
2
):
112
6
.
[PubMed]
1533-4023
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.